Innovation Pipeline Automation for GSK Consumer Health: 30% Time Savings and Doubling Innovation Margins
The Challenge
GSK CH’s Innovation Pipeline was evolving, moreso after a recent merger, and it was imperative to be able to see all the different performance measures in one place across all products launching over the next 5 years, the general layout of the challenge was that: The innovation pipeline therefore can be expected to be broad in terms of quantity, value, and innovation types.
Data integrity needed to be maintained, that included process setting, stakeholder management, and Data Quality Management automated process design and implementation.
Unified metrics and KPIs needed to be captured and reported across all governances of the organization
Insights for prioritization and resource allocation needed to be automated for governance meetings and portfolio leadership
The time from analysis to action was extravagant, each governance had its own practices that it wanted to stick to, and the data pipeline was full of inadequate
steps that hinder data integrity. An automated solution was a dire need.
The Solution
An Automated, Data-Driven Pipeline for Unified Innovation Management
We partnered with GSK CH to develop a five-step process that automated critical elements of their innovation pipeline, resulting in a suite of analytics tools for informed decision-making. This solution allowed executives to reclaim 30% of their time and contributed to doubling GSK CH’s innovation growth margins. Key features included:
- Automated Data Quality Management: Ensuring data integrity through automated checks and balances within the pipeline, eliminating errors and inconsistencies.
- Unified Metrics Dashboard: A centralized dashboard capturing all relevant KPIs and metrics across governance levels, providing clear visibility and streamlined reporting.
- Prioritization and Resource Allocation Insights: An automated prioritization model tailored to meet the needs of diverse governance practices, facilitating swift, data-driven decisions in governance and portfolio leadership meetings.
The Result
30% Reduction in Executive Time and Doubling of Innovation Growth Margins
By creating a cohesive and automated solution, GSK CH successfully cut down time spent on manual analysis and decision-making, while achieving a 100% increase in their innovation growth rate.
